•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
WuXi Biologics (2269.HK) announced that it has been named by Morningstar Sustainalytics as both an Industry ESG Leader and a Regional ESG Leader for 2026, marking the sixth consecutive year the company has received the recognition. The award highlights WuXi Biologics’ commitment to advancing sustainability across its global business operations and value chain, and reflects the progress of its long-term sustainability strategy and its vision as a “Green CRDMO” leader.
Morningstar Sustainalytics is an independent ESG research, ratings, and analytics provider that supports global investors in responsible investment strategies. For its 2026 ESG Risk Ratings, the provider assessed around 15,000 companies across 42 industries. ESG Leader distinctions were awarded to companies demonstrating robust ESG risk management and performance relative to peers across industries and regions.
In July 2025, WuXi Biologics was also placed in Sustainalytics’ highest ESG rating tier of negligible risk, achieving a top 1% global ranking score.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, said: “We are honored to once again be recognized by Morningstar Sustainalytics. As a proactive leader in sustainability, we are committed to collaborating with all stakeholders to create positive social and environmental impacts, empowering our global clients through end-to-end Green CRDMO solutions, and advancing responsible practices across the entire value chain.”
He added that the company aims to drive equal availability and affordability to innovative therapeutics worldwide by accelerating the journey from molecules to market, enabling innovative biologics to reach patients faster, at greater scale, and with consistent quality.
WuXi Biologics said its sustainability efforts have been recognized by multiple global ESG rating agencies over the years, including:
WuXi Biologics (2269.HK) is a global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics—from concept to commercialization—for patients worldwide.
The company said it has over 13,000 employees across China, the United States, Ireland, Germany, and Singapore, including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence. It also stated that, as of December 31, 2025, it is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the project portfolio.
WuXi Biologics said sustainability is a cornerstone of its long-term business growth, and that it continuously drives technology innovations to provide end-to-end “Green CRDMO” solutions while demonstrating Environmental, Social and Governance (ESG) practices.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
